stockrowXenon Pharmaceuticals Inc.
XENE Healthcare Biotechnology
Xenon Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $7.5 million, down 20.5% from fiscal 2022.
- Revenue
- +100.7%
- EPS
- −3.74%
- Free cash flow
- −48.6%
Quarter to June 2026, against a year earlier
Follow XENE
Alert me
Xenon Pharmaceuticals Inc. (XENE) Current ratio
Xenon Pharmaceuticals Inc.'s current ratio at the end of the quarter to 30 June 2026 was 21.0×, up 7.6× from fiscal 2025 (13.4×). Over the past ten years it has ranged from 3.3× (fiscal 2019) to 39.0× (fiscal 2021); the current reading is higher than 36% of that period. That is above the Biotechnology industry median of 4.9× and above the Healthcare sector median of 3.1×.
Current ratio, annual
Embed this chart
Annual newest first
| Period | Current ratio | Change |
|---|---|---|
| FY2025 | 13.4× | (24.84%) |
| FY2024 | 17.8× | (24.52%) |
| FY2023 | 23.6× | (10.57%) |
| FY2022 | 26.4× | (32.25%) |
| FY2021 | 39.0× | 217.38% |
| FY2020 | 12.3× | 268.27% |
| FY2019 | 3.3× | (88.66%) |
| FY2018 | 29.5× | 168.34% |
| FY2017 | 11.0× | (40.06%) |
| FY2016 | 18.3× | (16.29%) |
Quarterly newest first
| Period | Current ratio | Change |
|---|---|---|
| Jun 2026 | 21.0× | (24.39%) |
| Mar 2026 | 27.8× | 107.19% |
| Dec 2025 | 13.4× | 7.11% |
| Sep 2025 | 12.5× | (17.26%) |
| 42 more quarters | Free account |
Against its own ten years
Current ratio against peers
| Company | Current ratio |
|---|---|
| TNGX Tango Therapeutics, Inc. compare | 50.8× |
| IRON Disc Medicine, Inc. compare | 24.1× |
| XENE Xenon Pharmaceuticals Inc. | 21.0× |
| RLAY Relay Therapeutics, Inc. compare | 18.3× |
| PBLS Parabilis Medicines, Inc. compare | 17.9× |
| ABCL AbCellera Biologics Inc. compare | 12.8× |
| VKTX Viking Therapeutics, Inc. compare | 7.3× |
| IOVA Iovance Biotherapeutics, Inc. compare | 5.2× |
| ACAD ACADIA Pharmaceuticals Inc. compare | 3.8× |
| Biotechnology industry median | 4.9× |
| Healthcare sector median | 3.1× |
| Market median | 1.6× |
What Current ratio is
Current Ratio shows whether a company’s short-term assets are enough to cover the bills and debts it must pay within the next year.
Current Assets (Total) ÷ Current Liabilities (Total)
More on XENE
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Altman Z-score
- The full statement